GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,807.50p
   
  • Change Today:
      19.00p
  • 52 Week High: 1,812.50
  • 52 Week Low: 1,316.00
  • Currency: UK Pounds
  • Shares Issued: 4,144.92m
  • Volume: 732,700
  • Market Cap: £74,920m
  • RiskGrade: 129

GSK Overview

We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of 2030. Our bold ambitions for patients are reflected in commitments to growth and a step-change in performance. We are a company where outstanding people can thrive.
Registrars: Equiniti
Brands: Lucozade, Horlicks, Ribena, Paxil, Seroxat

Key Personnel

CEO: Emma Walmsley
Chief Finance Officer: Julie Brown
Independent Non-Executive Director: Harry (Hal) C. Dietz
Independent Non-Executive Director: Jesse Goodman
Independent Non-Executive Director: Vishal Sikka
Independent Non-Executive Director: Elizabeth (Liz) McKee Anderson
Independent Non-Executive Director: Anne Beal
Non-Executive Chairman: Jonathan Symonds
Senior Independent Non-Executive Director: Charles Bancroft
Non-Executive Dir: Wendy Becker , Jeannie Lee , Hal Barron

Contact Details

Address: 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS
Phone: +44 (0)20 8047 5000
Website: http://www.gsk.com

Listings

Sector: Pharma and Biotech(LSE)
Index: techMARKFTSE 100FTSE 350FTSE All-Share
Overseas Listings: BATSLON:GSKL, NYSE:GSK
ISIN: GB00BN7SWP63

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

GSK Market Data

Currency UK Pounds
Share Price 1,807.50p
Change Today 19.00p
% Change 1.06 %
52 Week High 1,812.50
52 Week Low 1,316.00
Volume 732,700
Shares Issued 4,144.92m
Market Cap £74,920m
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
60.03% below the market average60.03% below the market average60.03% below the market average60.03% below the market average60.03% below the market average
21.57% above the sector average21.57% above the sector average21.57% above the sector average21.57% above the sector average21.57% above the sector average
Price Trend
49.74% above the market average49.74% above the market average49.74% above the market average49.74% above the market average49.74% above the market average
59.26% above the sector average59.26% above the sector average59.26% above the sector average59.26% above the sector average59.26% above the sector average
Income
9.60% above the market average9.60% above the market average9.60% above the market average9.60% above the market average9.60% above the market average
14.29% below the sector average14.29% below the sector average14.29% below the sector average14.29% below the sector average14.29% below the sector average
Growth
20.51% below the market average20.51% below the market average20.51% below the market average20.51% below the market average20.51% below the market average
29.41% above the sector average29.41% above the sector average29.41% above the sector average29.41% above the sector average29.41% above the sector average

What The Brokers Say

Strong Buy 8
Buy 5
Neutral 9
Sell 2
Strong Sell 0
Total 24
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q1 Q4
Ex-Div 16-May-24 22-Feb-24
Paid 11-Jul-24 11-Apr-24
Amount 15.00p 16.00p

Trades for 23-May-2024

Time Volume / Share Price
10:53 260 @ 1,807.25p
10:53 10 @ 1,807.25p
10:53 9 @ 1,807.50p
10:52 19 @ 1,807.50p
10:52 800 @ 1,807.24p

GSK Key Personnel

CEO Emma Walmsley

Top of Page